Results 221 to 230 of about 3,253,670 (325)

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández, Alejandra Ramos, Ana Montero‐Calle, Pablo Cabezas‐Sainz, Maria J Barrero, Diego Megías, Borja Vilaplana‐Martí, Carolina Epifano, Déborah Gómez‐Dominguez, Sara Monzón, Isabel Cuesta, Laura Sánchez, Rodrigo Barderas, Jesús García‐Donas, Alberto Martín, Ignacio Pérez de Castro   +17 more
wiley   +1 more source

Out-of-hospital births and the experiences of emergency ambulance clinicians and birthing parents: a scoping review of the literature. [PDF]

BMJ Open
Hill M, Miles A, Flanagan B, Hansen S, Mills B, Hopper L.   +5 more
europepmc   +1 more source

Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas

Molecular Oncology, Volume 19, Issue 4, Page 984-993, April 2025.
Tumor‐informed whole‐genome sequencing (MRD‐EDGESNV) was applied to detect circulating tumor DNA (ctDNA) in patients with colorectal adenomas. Using a 95% specificity threshold, established from stage III colorectal cancer patients, ctDNA was detected in 50% of symptomatic and 25% of asymptomatic adenoma cases with median tumor fractions of 5.9 × 10−5 ...
Amanda Frydendahl, Adam J. Widman, Nadia Øgaard, Anushri Arora, Daniel Halmos, Jesper Nors, Johanne Ahrenfeldt, Tenna V. Henriksen, Christina Demuth, Line Raaby, Mads H. Rasmussen, Christina Therkildsen, Dan A. Landau, Claus L. Andersen   +13 more
wiley   +1 more source

Assessing the Dissemination of Federal Risk Communication by News Media Outlets During Enteric Illness Outbreaks: Canadian Content Analysis.

JMIR Public Health Surveill
Shereefdeen H, Grant LE, Patel V, MacKay M, Papadopoulos A, Cheng L, Phypers M, McWhirter JE.   +7 more
europepmc   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

Molecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Editorial: Professional identities within healthcare professions education. [PDF]

Front Med (Lausanne)
Sawatsky AP, Monrouxe LV.
europepmc   +1 more source

Clinical significance of stratifying prostate cancer patients through specific circulating genes

Molecular Oncology, Volume 19, Issue 5, Page 1310-1331, May 2025.
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian, Edouard Jarry, Arynne Santos, Quentin Vesval, Lucie Hamel, Rafael Sanchez‐Salas, Alexis Rompré‐Brodeur, Wassim Kassouf, Raghu Rajan, Fadi Brimo, Marie Duclos, Armen Aprikian, Simone Chevalier   +12 more
wiley   +1 more source

Advancing the assessment of clinical competence in Latin America: a scoping review of OSCE implementation and challenges in resource-limited settings. [PDF]

BMC Med Educ
Armijo-Rivera S, Fuenzalida-Muñoz B, Vicencio-Clarke S, Elbers-Arce A, Bozzo-Navarrete S, Kunakov N, Miranda-Hurtado C, Shibao-Miyasato H, Sanhueza J, Cornejo C, Soublette A, Sandoval AM, Casas-Bueno FC, Delgado X.   +13 more
europepmc   +1 more source

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

Molecular Oncology, EarlyView.
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin, Audrey Vinchent, Marie Fernandes, Isabelle Damour, Agathe Laratte, Rémi Tellier, Gabriella O. Estevam, Jean‐Pascal Meneboo, Céline Villenet, Clotilde Descarpentries, James S. Fraser, Martin Figeac, Alexis B. Cortot, Etienne Rouleau, David Tulasne   +14 more
wiley   +1 more source

Evolution of reported patient and public involvement over time in randomised controlled trials in major medical journals and in their protocols: meta-epidemiological evaluation.

BMJ
Vanneste A, Wens I, Sinnaeve P, Louati C, Huys I, Ioannidis JPA, Adriaenssens T.   +6 more
europepmc   +1 more source